Exosome Proteomics to Detect Eyrthropoietin (EPO) Use in Athletes
试验速览
- 阶段
- 不适用
- 发起方
- 入组人数
- 72
- 试验地点
- 1
- 主要终点
- Blood proteome enrichment pathway analysis in GO annotation
研究概览
简要总结
The role of exosomes in cell signalling has only recently been appreciated and is a hugely exciting and rapidly growing area, and combined with LC-MS/MS proteomics, can overcome traditional barriers to proteomics in doping applications. To our knowledge, no research has yet been undertaken to explore whether the highly promising combination of exosome proteomics has utility for rhEPO detection. The applications are extensive; the diagnostic value of differentially regulated proteins could be further validated against the existing IEF EPO WADA accredited tests using samples collected during this study, used to study altitude hypoxia versus exogenous EPO administration (WADA current targeted research 2017), investigated as a platform approach to ESA and HIF agents more generally, as well as facilitate development of direct ELISA high throughput tests.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Basic Science
- 盲法
- Triple (Participant, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 45 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •VO2max of at least 55+/-2 for men and 50+/-2 for women
- •BMI between 18 and 27
- •Resting hematocrit of less than 46%
排除标准
- •Chronic disease deemed by the medical doctor to affect the outcome
- •Competitive athlete subject to doping control
- •Use of other prescription medicine deemed by the medical doctor to interact with the study drug
- •Allergy or otherwise unacceptable side effects toward the study drug
- •Pregnancy
研究组 & 干预措施
EPO II
Erythropoetin infusion (20 IU/kg)
干预措施: Erythropoietin (Drug)
Placebo
Saline infusion
干预措施: Placebo (Drug)
EPO
Erythropoetin infusion (9 IU/kg)
干预措施: Erythropoietin (Drug)
结局指标
主要结局
Blood proteome enrichment pathway analysis in GO annotation
时间窗: At baseline and after week 3 of treatment
Change in enrichment (measured in blood and assessed using GO annotation)
次要结局
- Blood markers of iron(At baseline and after week 3 of treatment)
研究者
Morten Hostrup, PhD
Associate Professor
University of Copenhagen